000283077 001__ 283077
000283077 005__ 20251229160656.0
000283077 0247_ $$2doi$$a10.1002/alz70860_106340
000283077 0247_ $$2pmid$$apmid:41435182
000283077 0247_ $$2pmc$$apmc:PMC12726296
000283077 0247_ $$2ISSN$$a1552-5260
000283077 0247_ $$2ISSN$$a1552-5279
000283077 037__ $$aDZNE-2025-01484
000283077 041__ $$aEnglish
000283077 082__ $$a610
000283077 1001_ $$aBosch, Iris$$b0
000283077 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283077 245__ $$aFrom zero to 6,000 in 9 months: Recruitment and innovation strategies for a remote longitudinal Alzheimer's population‐based screening study – Insights from the REAL AD study
000283077 260__ $$c2025
000283077 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767020675_31207
000283077 3367_ $$033$$2EndNote$$aConference Paper
000283077 3367_ $$2BibTeX$$aINPROCEEDINGS
000283077 3367_ $$2DRIVER$$aconferenceObject
000283077 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283077 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283077 3367_ $$2ORCID$$aOTHER
000283077 520__ $$aThe REAL AD study aims to validate the diagnostic and prognostic performance of combining blood-based biomarkers and remote cognitive testing as a screening approach for early Alzheimer's disease (AD), leveraging an existing healthcare infrastructure in Western Sweden. Here, we discuss strategies for recruiting a large and representative cohort, demographics and participant retention during the first study phase, and evaluate the process of implementing innovations enabling a fully remote study design.In April 2024, a recruitment campaign was launched in collaboration with a PR company to recruit at least 3000 participants between 50-80 years from the general population. Through an online study platform, participants were enrolled and asked to answer health and lifestyle questionnaires (Step 1), guided to remotely administered cognitive testing (Step 2; using the neotivTrials app or Cognitron battery), and blood sampling at any of the 105 public regional primary care units (Step 3; Figure 1). Additionally, optional remote blood sampling complemented the primary study protocol.At abstract submission, N = 6092 participants (mean age=63.9 years, 70% female) were enrolled over a nine-month period, with recruitment ongoing for another month (Table 1). Retention rates for initial study steps were N = 4785 participants at Step 1, N = 3860 at Step 2, and N = 2491 at Step 3. These rates align with or exceed findings from a cross-study evaluation of retention in remote digital health studies (Pratap et al., 2020). Innovations enabling a fully remote study design were critical in achieving these recruitment and retention rates. However, attrition highlights challenges in maintaining engagement in remote study designs. Key innovations will be evaluated, focusing on: (1) an online study platform with secure authentication, (2) remote cognitive testing, (3) blood sampling via local healthcare providers, and (4) remote sample collection, all achieved through collaboration with relevant stakeholders. Structured feedback reports from participants will complement evaluations.REAL AD demonstrates the feasibility of implementing a large-scale, fully remote screening approach for early AD. Preliminary results highlight the effectiveness of key innovations and stakeholder collaboration, though attrition underlines the need to address engagement barriers. Future improvements and recommendations for other remote population-based screening initiatives will be discussed.
000283077 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283077 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283077 650_7 $$2NLM Chemicals$$aBiomarkers
000283077 650_2 $$2MeSH$$aHumans
000283077 650_2 $$2MeSH$$aFemale
000283077 650_2 $$2MeSH$$aMale
000283077 650_2 $$2MeSH$$aAged
000283077 650_2 $$2MeSH$$aMiddle Aged
000283077 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000283077 650_2 $$2MeSH$$aAlzheimer Disease: blood
000283077 650_2 $$2MeSH$$aPublic Health
000283077 650_2 $$2MeSH$$aAged, 80 and over
000283077 650_2 $$2MeSH$$aBiomarkers: blood
000283077 650_2 $$2MeSH$$aSweden
000283077 650_2 $$2MeSH$$aNeuropsychological Tests
000283077 650_2 $$2MeSH$$aSurveys and Questionnaires
000283077 650_2 $$2MeSH$$aTelemedicine
000283077 650_2 $$2MeSH$$aPatient Selection
000283077 7001_ $$aLenér, Frida$$b1
000283077 7001_ $$aStankeviciute, Laura$$b2
000283077 7001_ $$aSingleton, Ellen Hanna$$b3
000283077 7001_ $$aÖhman, Fredrik$$b4
000283077 7001_ $$aQuitz, Kajsa$$b5
000283077 7001_ $$aDottori, Maria$$b6
000283077 7001_ $$0P:(DE-2719)2812972$$aBerron, David$$b7$$udzne
000283077 7001_ $$aFranzmeier, Nicolai$$b8
000283077 7001_ $$aKern, Silke$$b9
000283077 7001_ $$aZetterberg, Henrik$$b10
000283077 7001_ $$aBlennow, Kaj$$b11
000283077 7001_ $$aSchöll, Michael$$b12
000283077 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70860_106340$$gVol. 21 Suppl 6, no. Suppl 6, p. e106340$$nSuppl 6$$pe106340$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283077 8564_ $$uhttps://pub.dzne.de/record/283077/files/DZNE-2025-1484.pdf$$yRestricted
000283077 8564_ $$uhttps://pub.dzne.de/record/283077/files/DZNE-2025-1484.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283077 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812972$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283077 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283077 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283077 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283077 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283077 9201_ $$0I:(DE-2719)5000070$$kAG Berron$$lClinical Cognitive Neuroscience$$x0
000283077 980__ $$aabstract
000283077 980__ $$aEDITORS
000283077 980__ $$aVDBINPRINT
000283077 980__ $$ajournal
000283077 980__ $$aI:(DE-2719)5000070
000283077 980__ $$aUNRESTRICTED